BioDelivery Sciences International (BDSI) Shares Up 6.9%

BioDelivery Sciences International, Inc. (NASDAQ:BDSI)’s share price shot up 6.9% during trading on Friday . The company traded as high as $3.15 and last traded at $3.10. 1,849,957 shares changed hands during trading, an increase of 290% from the average session volume of 473,912 shares. The stock had previously closed at $2.90.

A number of brokerages recently commented on BDSI. ValuEngine raised BioDelivery Sciences International from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. Cantor Fitzgerald set a $5.00 price target on BioDelivery Sciences International and gave the company a “buy” rating in a research note on Tuesday, June 5th. HC Wainwright dropped their price target on BioDelivery Sciences International from $4.00 to $3.50 and set a “buy” rating for the company in a research note on Wednesday, May 23rd. Finally, Roth Capital set a $4.00 price target on BioDelivery Sciences International and gave the company a “buy” rating in a research note on Friday, May 11th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $4.07.

The company has a current ratio of 1.40, a quick ratio of 1.13 and a debt-to-equity ratio of 35.82.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings results on Thursday, May 10th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.03. BioDelivery Sciences International had a negative return on equity of 388.58% and a negative net margin of 122.75%. The company had revenue of $11.28 million during the quarter, compared to analyst estimates of $10.77 million. sell-side analysts expect that BioDelivery Sciences International, Inc. will post -0.68 EPS for the current year.

In other BioDelivery Sciences International news, Director Mark A. Sirgo sold 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 10th. The stock was sold at an average price of $2.06, for a total transaction of $206,000.00. Following the sale, the director now directly owns 2,585,966 shares in the company, valued at $5,327,089.96. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Paolantonio Ernest Robert De sold 64,155 shares of the company’s stock in a transaction that occurred on Friday, April 6th. The shares were sold at an average price of $2.09, for a total value of $134,083.95. Following the sale, the chief financial officer now owns 97,731 shares in the company, valued at $204,257.79. The disclosure for this sale can be found here. Corporate insiders own 9.00% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Two Sigma Investments LP purchased a new stake in BioDelivery Sciences International during the fourth quarter valued at approximately $166,000. Wells Fargo & Company MN raised its position in BioDelivery Sciences International by 88.9% during the fourth quarter. Wells Fargo & Company MN now owns 67,081 shares of the specialty pharmaceutical company’s stock valued at $198,000 after purchasing an additional 31,575 shares during the period. BlueCrest Capital Management Ltd purchased a new stake in BioDelivery Sciences International during the fourth quarter valued at approximately $201,000. Goldman Sachs Group Inc. purchased a new stake in BioDelivery Sciences International during the fourth quarter valued at approximately $223,000. Finally, Knott David M purchased a new stake in BioDelivery Sciences International during the first quarter valued at approximately $270,000. Institutional investors and hedge funds own 46.13% of the company’s stock.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply